The proposed role for the gut and mucosal immune defence mechanisms in inflammatory arthritides has been studied in various ways. In rheumatoid arthritis and ankylosing spondylitis serological, bacteriological, histopathological, and radioisotope methods have provided substantial but not unequivocal support for the role of the gut in inflammatory arthritides. Persistently raised serum concentrations of IgA have been interpreted as signs of stimulation of the secretory immune system, perhaps through the gastrointestinal tract. 5 Other findings that might support a role for IgA in inflammatory arthritides are IgA deposition in dermal vessels ofpatients with ankylosing spondylitis at biopsy6 and circulating IgA containing immune complexes in patients with ankylosing spondylitis with haematuria. 7 The clinical efficacy of sulphasalazine in ankylosing spondylitis and rheumatoid arthritis is by now well reported.8 9 
Results
The The idea was to investigate the possibility that potential local effects of sulphasalazine in the gut might be reflected as changes in the outflow of these cells from the gut.
The results show that a substantial decrease in numbers of IgA producing cells occurred early after onset of sulphasalazine treatment in all the 15 patients with inflammatory arthritides investigated. In most patients this decrease was apparent after only three weeks of sulphasalazine treatment-that is, before clinical improvement has been seen in previous studies.8 18 In fact, other authors have suggested that a longer treatment period than three months is needed for a fair evaluation of the drug." Thus clinically detectable treatment effects are unlikely to have occurred at three weeks after institution of sulphasalazine. Patients and controls show similar numbers of IgA producing cells before treatment, but this does not rule out the possibility that these cells are involved in pathogenetic or therapeutic mechanisms.
Notably, the decrease in serum IgA concentrations that was seen in this and in previous studies'0 1' was not apparent until after a longer sulphasalazine treatment time. This suggests that different mechanisms are responsible for the sulphasalazine dependent effects on circulating IgA producing cells and serum concentrations of IgA respectively; the half life of serum IgA is only about four days,'9 excluding slow clearance of the serum pool of IgA as a reason for the slow effects on serum IgA concentrations. Interestingly, most serum IgA seems to derive from IgA producing cells in the bone marrow, whereas the circulating IgA producing cells mainly originate from mucosal sites-that is, to a large extent from the intestine."' Against this background it is tempting to suggest that the rapid effect of sulphasalazine on numbers of circulating IgA producing cells should be due to effects of sulphasalazine in the intestine, whereas the slower effects on serum IgA may be due to systemic effects on bone marrow cells, effects that may even be secondary to a general decrease in inflammatory activity in the body.
Our findings suggest that sulphasalazine produces its effects on numbers of circulating IgA producing cells by a local effect in the intestine. Such an effect could obviously be due both to direct action of sulphasalazine on the production and export of IgA producing cells in the intestine or occur indirectly after primary effects of sulphasalazine on the gastrointestinal bacterial flora.
One possibility is that sulphasalazine, present in high concentrations in the intestine, exerts a local immunosuppressive effect on T cells regulating IgA committed cells or acts directly on IgA producing B cells, as described in vitro for antibody production at these concentrations of the drug.20 If this were the case the early effects of sulphasalazine on IgA production shown in this study would also be indirect evidence that immunological events occurring in the gastrointestinal tract may precede improvement of arthritis. If confirmed, this method of enumerating and, possibly, determining specificities of circulating IgA producing cells may be useful in further studies both on the mode of action of sulphasalazine in arthritis and on the potential role of mucosal immunity in rheumatoid arthritis and ankylosing spondylitis. 
